Veradigm (NASDAQ:MDRX) Shares Up 10.5% - Here's Why

Key Points

• Shares of Veradigm jumped 10.5% to $4.65 mid-day, but the move occurred on just 3,404 shares traded — about 99% below the average session volume — suggesting limited participation.
• Wall Street Zen upgraded Veradigm to a hold rating on March 7.
• Veradigm is a healthcare-technology provider of EHR, practice-management and revenue-cycle solutions, with a market capitalization of $468.27 million, a P/E of 23.25, and 50-day/200-day SMAs of $4.51 and $4.67, respectively.

Veradigm Inc. (NASDAQ:MDRX - Get Free Report) shares shot up 10.5% during mid-day trading on Tuesday . The stock traded as high as $4.65 and last traded at $4.65. 3,404 shares traded hands during trading, a decline of 99% from the average session volume of 234,028 shares. The stock had previously closed at $4.21.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Veradigm to a "hold" rating in a research note on Saturday, March 7th.

Veradigm Stock Up 2.1%

The company has a market capitalization of $468.27 million, a P/E ratio of 23.25 and a beta of 0.56. The business has a 50 day simple moving average of $4.51 and a 200-day simple moving average of $4.67.

Veradigm Company Profile

Veradigm, Inc NASDAQ: MDRX is a healthcare technology company that provides a comprehensive suite of clinical, financial and analytical solutions to medical practices, health systems and life sciences organizations. The company's offerings are designed to streamline electronic health record (EHR) workflows, optimize revenue cycle management and improve patient engagement through integrated software modules and cloud-based platforms.

Veradigm's product portfolio includes EHR and practice management systems tailored to ambulatory and specialty care settings, as well as revenue cycle management services that encompass billing, coding and claims processing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.